COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
Public ClinicalTrials.gov record NCT00952289. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was a randomized, double-blind study comparing the efficacy and safety of ruxolitinib (INCB018424) tablets to matching placebo tablets in patients diagnosed with Myelofibrosis (either Primary Myelofibrosis (PMF) or Post-Polycythemia Vera Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).
Study identification
- NCT ID
- NCT00952289
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 309 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2009
- Primary completion
- Oct 31, 2010
- Completion
- Sep 30, 2015
- Last update posted
- Mar 11, 2018
2009 – 2015
United States locations
- U.S. sites
- 88
- U.S. states
- 36
- U.S. cities
- 88
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Scottsdale | Arizona | — | — |
| Not listed | Baldwin Park | California | — | — |
| Not listed | Bellflower | California | — | — |
| Not listed | Beverly Hills | California | — | — |
| Not listed | Corona | California | — | — |
| Not listed | Fullerton | California | — | — |
| Not listed | Highland | California | — | — |
| Not listed | La Jolla | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Orange | California | — | — |
| Not listed | Palo Alto | California | — | — |
| Not listed | Panorama City | California | — | — |
| Not listed | Rancho Cucamonga | California | — | — |
| Not listed | Riverside | California | — | — |
| Not listed | Sacramento | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | West Covina | California | — | — |
| Not listed | Aurora | Colorado | — | — |
| Not listed | Denver | Colorado | — | — |
| Not listed | Fort Collins | Colorado | — | — |
| Not listed | Norwalk | Connecticut | — | — |
| Not listed | Washington D.C. | District of Columbia | — | — |
| Not listed | Boynton Beach | Florida | — | — |
| Not listed | Gainesville | Florida | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | West Palm Beach | Florida | — | — |
| Not listed | Winter Park | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Augusta | Georgia | — | — |
| Not listed | Honolulu | Hawaii | — | — |
| Not listed | Boise | Idaho | — | — |
| Not listed | Meridian | Idaho | — | — |
| Not listed | Twin Falls | Idaho | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Beech Grove | Indiana | — | — |
| Not listed | Indianapolis | Indiana | — | — |
| Not listed | Ames | Iowa | — | — |
| Not listed | Iowa City | Iowa | — | — |
| Not listed | Sioux City | Iowa | — | — |
| Not listed | Waterloo | Iowa | — | — |
| Not listed | Louisville | Kentucky | — | — |
| Not listed | Alexandria | Louisiana | — | — |
| Not listed | New Orleans | Louisiana | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Ann Arbor | Michigan | — | — |
| Not listed | Detroit | Michigan | — | — |
| Not listed | Novi | Michigan | — | — |
| Not listed | Southfield | Michigan | — | — |
| Not listed | Minneapolis | Minnesota | — | — |
| Not listed | Rochester | Minnesota | — | — |
| Not listed | Saint Louis Park | Minnesota | — | — |
| Not listed | New Albany | Mississippi | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Billings | Montana | — | — |
| Not listed | Denville | New Jersey | — | — |
| Not listed | Hackensack | New Jersey | — | — |
| Not listed | Morristown | New Jersey | — | — |
| Not listed | Somerville | New Jersey | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | East Setauket | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Valhalla | New York | — | — |
| Not listed | Durham | North Carolina | — | — |
| Not listed | Hickory | North Carolina | — | — |
| Not listed | Winston-Salem | North Carolina | — | — |
| Not listed | Bismarck | North Dakota | — | — |
| Not listed | Akron | Ohio | — | — |
| Not listed | Canton | Ohio | — | — |
| Not listed | Cleveland | Ohio | — | — |
| Not listed | Dayton | Ohio | — | — |
| Not listed | Dover | Ohio | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Pittsburgh | Pennsylvania | — | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Germantown | Tennessee | — | — |
| Not listed | Memphis | Tennessee | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | New Braunfels | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Burlington | Vermont | — | — |
| Not listed | Everett | Washington | — | — |
| Not listed | Seattle | Washington | — | — |
| Not listed | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00952289, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 11, 2018 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00952289 live on ClinicalTrials.gov.